This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferri, C. Articles by Balsano, F. Search for Related Content PubMed PubMed Citation Articles by Ferri, C. Articles by Balsano, F.

Hypertension, Vol 21, 875-881, Copyright © 1993 by American Heart Association

ARTICLES

Enhanced blood pressure response to cyclooxygenase inhibition in salt- sensitive human essential hypertension

C Ferri, C Bellini, A Piccoli, A Carlomagno, MS Bonavita, A Santucci and F Balsano
Institute of I Clinica Medica, Andrea Cesalpino Foundation, University La Sapienza, Rome, Italy.

To evaluate the influence of salt sensitivity on the blood pressure response to oral indomethacin treatment, we studied 35 hospitalized essential hypertensive patients (24 men and 11 women, aged from 40 to 55 years). During a normal NaCl intake (120 mmol Na+ per day), patients were assigned to receive in a randomized double-blind fashion either 200 mg indomethacin (25 patients) or placebo (10 patients) for 5 days. Two weeks after the interruption of indomethacin treatment, during which the normal NaCl intake was continued, salt sensitivity was assessed by giving each patient a high (220 mmol Na+ per day for 10 days) and then a low (20 mmol Na+ per day for 10 days) NaCl diet. Blood pressure changes were evaluated, and the measurement taken at the end of the 2 weeks under normal sodium intake was considered baseline blood pressure. Patients were classified as salt sensitive when a diastolic blood pressure change of 10 mm Hg or more occurred after both low and high periods of sodium intake. In salt-resistant patients treated with indomethacin (n = 12, nine men and three women, mean age 50.5 +/- 3.7 years), neither blood pressure (systolic blood pressure from 150.8 +/- 11.2 to 154.6 +/- 9.3 mm Hg, NS; diastolic blood pressure from 99.3 +/- 2.1 to 101.1 +/- 4.4 mm Hg, NS) nor the urinary Na+ excretion (from 108.1 +/- 20.9 to 97.9 +/- 9.1 mmol/24 hr, NS) was significantly affected by the drug.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				P. PERINOTTO, A. BIGGI, N. CARRA, A. ORRICO, G. VALMADRE, P. DALL'AGLIO, A. NOVARINI, and A. MONTANARI Angiotensin II and Prostaglandin Interactions on Systemic and Renal Effects of L-NAME in Humans J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1706 - 1712. [Abstract] [Full Text] [PDF]

				M. T. Llinas, J. D. Gonzalez, F. Rodriguez, E. Nava, S. Taddei, and F. J. Salazar Renal Changes Induced by Nitric Oxide and Prostaglandin Synthesis Reduction : Effects of Trandolapril and Verapamil Hypertension, February 1, 1998; 31(2): 657 - 664. [Abstract] [Full Text] [PDF]

				S.-S. Bolz and U. Pohl Indomethacin enhances endothelial NO release -- evidence for a role of PGI2 in the autocrine control of calcium-dependent autacoid production Cardiovasc Res, December 1, 1997; 36(3): 437 - 444. [Abstract] [Full Text] [PDF]